Squarepoint Ops LLC Sells 25,257 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Squarepoint Ops LLC reduced its Halozyme Therapeutics stake by 40.5%, selling 25,257 shares and retaining 37,035 shares worth approximately $2.9 million. Institutional investors collectively own 97.79% of the company.
• Company insiders sold 72,478 shares valued at $7.37 million over the past three months, including CEO Helen Torley’s sale of 20,000 shares under a pre-arranged Rule 10b5-1 plan.
• Halozyme reported stronger-than-expected quarterly results, with EPS of $2.28 versus the $1.79 consensus and revenue up 47.7% year over year to $481 million. Analysts maintain a “Moderate Buy” consensus, although the average price target of $91.20 is below the stock’s $107.20 opening price.

Squarepoint Ops LLC cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 40.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,035 shares of the biopharmaceutical company's stock after selling 25,257 shares during the quarter. Squarepoint Ops LLC's holdings in Halozyme Therapeutics were worth $2,899,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of HALO. Measured Wealth Private Client Group LLC increased its position in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 124 shares during the last quarter. Abel Hall LLC increased its holdings in shares of Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company's stock valued at $216,000 after acquiring an additional 129 shares during the last quarter. StoneX Group Inc. raised its stake in shares of Halozyme Therapeutics by 3.8% in the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company's stock valued at $246,000 after acquiring an additional 132 shares in the last quarter. Twin Capital Management Inc. lifted its holdings in Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company's stock worth $738,000 after purchasing an additional 161 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its holdings in Halozyme Therapeutics by 1.9% in the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company's stock worth $654,000 after purchasing an additional 165 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $107.24, for a total transaction of $2,144,800.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $82,336,727.20. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the company's stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares of the company's stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 72,478 shares of company stock valued at $7,370,004 over the last three months. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $107.20 on Monday. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $111.15. The company has a fifty day moving average price of $93.73 and a 200 day moving average price of $77.01. The stock has a market cap of $12.17 billion, a P/E ratio of 32.00, a PEG ratio of 0.41 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business's quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the business posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on HALO. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. Leerink Partners raised shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Benchmark restated a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, TD Cowen raised their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Halozyme Therapeutics has an average rating of "Moderate Buy" and an average target price of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.